A Phase 1 interventional study of MET-2 in Depression, Anxiety, sponsored by NuBiyota. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-08-11.
Sponsored by NuBiyota · Phase 1, Interventional, and Treatment
This study will measure the effects of MET-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety and other symptoms of depression, such as sleep and anhedonia.
This study will measure the effects of MET-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety and other symptoms of depression, such as sleep and anhedonia.
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 21 is below the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →NuBiyota is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
MET-2 will be given to subjects with major depression disorder and its effect on mood will be measured
Biological: MET-2
MET-2 will be given to subjects with generalized anxiety disorder and its effect on mood will be measured
Biological: MET-2
Subjects will take study medication once daily for the duration of the study
Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders
Time frame: Week 10
Generalized Anxiety Disorder - 7 (GAD-7)
The GAD-7 is a seven domain, self-reported questionnaire for screening and assessing severity of generalized anxiety disorder.
Time frame: Week 10
Plan to share: No — IPD will not be shared with other researchers.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NuBiyota